FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306385659> ?p ?o ?g. }

• W4306385659 abstract "During many years, chemo-immunotherapy fludarabine-cyclophosphamide-rituximab (FCR) was the gold standard for first line treatment of medically fit patients with symptomatic B-chronic lymphocytic leukemia (CLL). Over the last decade, targeted biotherapies have revolutionized the treatment of B-CLL patients and almost entirely supplanted FCR. However, no biomarker still exists to predict the complete remission (CR) with undetectable minimal residual disease (uMRD) in bone marrow (BM), which remains the best predictive factor for survival. MicroRNAs represent a class of molecular biomarkers which expression is altered in B-CLL. Our study aimed at identifying before treatment blood miRNAs that predict treatment outcome in previously untreated B-CLL patients (NCT01370772, https://clinicaltrials.gov/ct2/show/NCT01370772). Using hierarchical clustering of miRNA expression profiles discriminating 8 patients who achieved CR with BM uMRD from 8 patients who did not achieve CR and displayed detectable BM MRD, we identified 25 miRNAs differentially expressed before treatment. The expression of 11 miRNAs was further validated on a larger cohort (n=123). Based on the dosage of 5 miRNAs at diagnosis, a decision tree was constructed to predict treatment outcome. We identified 6 groups of patients with a distinct probability of being CR with BM uMRD to FCR treatment, ranging from 72% (miR-125b, miR-15b and miR-181c high) to 4% (miR-125b and miR-193b low). None of the patients displaying high expression levels of miR-125b, miR-15b and miR-181c relapsed during study follow-up. In contrast, patients with low miR-15b and high miR-412, or with low miR-125b and miR-193b, demonstrated significant low PFS. RNA sequencing of blood at diagnosis identified that patients relapsing after treatment are characterized by significant enrichment of gene signatures related to cell cycle, MYC target genes, metabolism and translation regulation. Conversely, patients achieving CR with BM uMRD displayed significant enrichment in genes related to communication between CLL cells and the microenvironment, immune system activation and upregulation of polycomb PRC2 complex target genes. Our results suggest that blood miRNAs are potent predictive biomarkers for FCR treatment efficacy and might be implicated in the FCR efficacy in B-CLL patients, providing new insight into unmet need for the treatment of B-CLL patients and identifying pathways predictive of patients' remission.ClinicalTrials.gov, identifier NCT01370772." @default.
• W4306385659 created "2022-10-17" @default.
• W4306385659 creator A5004617126 @default.
• W4306385659 creator A5006506403 @default.
• W4306385659 creator A5009502823 @default.
• W4306385659 creator A5027482571 @default.
• W4306385659 creator A5031977714 @default.
• W4306385659 creator A5039690700 @default.
• W4306385659 creator A5045707345 @default.
• W4306385659 creator A5045965285 @default.
• W4306385659 creator A5050595115 @default.
• W4306385659 creator A5058103666 @default.
• W4306385659 creator A5074440260 @default.
• W4306385659 date "2022-10-17" @default.
• W4306385659 modified "2023-10-09" @default.
• W4306385659 title "miRNA profile at diagnosis predicts treatment outcome in patients with B-chronic lymphocytic leukemia: A FILO study" @default.
• W4306385659 cites W1821376442 @default.
• W4306385659 cites W1932017899 @default.
• W4306385659 cites W1949731480 @default.
• W4306385659 cites W1977186288 @default.
• W4306385659 cites W1986976471 @default.
• W4306385659 cites W2007430145 @default.
• W4306385659 cites W2016818600 @default.
• W4306385659 cites W2021269639 @default.
• W4306385659 cites W2021584746 @default.
• W4306385659 cites W2021628104 @default.
• W4306385659 cites W2037980270 @default.
• W4306385659 cites W2048547076 @default.
• W4306385659 cites W2053302777 @default.
• W4306385659 cites W2063123633 @default.
• W4306385659 cites W2066357502 @default.
• W4306385659 cites W2069540657 @default.
• W4306385659 cites W2074429834 @default.
• W4306385659 cites W2083189124 @default.
• W4306385659 cites W2085419928 @default.
• W4306385659 cites W2102036352 @default.
• W4306385659 cites W2115093090 @default.
• W4306385659 cites W2116257819 @default.
• W4306385659 cites W2135314242 @default.
• W4306385659 cites W2137542120 @default.
• W4306385659 cites W2140273359 @default.
• W4306385659 cites W2142099365 @default.
• W4306385659 cites W2151177887 @default.
• W4306385659 cites W2152575748 @default.
• W4306385659 cites W2154499913 @default.
• W4306385659 cites W2158214783 @default.
• W4306385659 cites W2160697532 @default.
• W4306385659 cites W2160844806 @default.
• W4306385659 cites W2169269721 @default.
• W4306385659 cites W2169456326 @default.
• W4306385659 cites W2179438025 @default.
• W4306385659 cites W2204188048 @default.
• W4306385659 cites W2221325899 @default.
• W4306385659 cites W2295348655 @default.
• W4306385659 cites W2308858788 @default.
• W4306385659 cites W2323490326 @default.
• W4306385659 cites W2407407749 @default.
• W4306385659 cites W2412674741 @default.
• W4306385659 cites W2581703858 @default.
• W4306385659 cites W2605172890 @default.
• W4306385659 cites W2607567607 @default.
• W4306385659 cites W2770853770 @default.
• W4306385659 cites W2785854718 @default.
• W4306385659 cites W2789661795 @default.
• W4306385659 cites W2792230705 @default.
• W4306385659 cites W2809508640 @default.
• W4306385659 cites W2949753513 @default.
• W4306385659 cites W2999929450 @default.
• W4306385659 cites W3087507522 @default.
• W4306385659 cites W3154374554 @default.
• W4306385659 cites W4256341283 @default.
• W4306385659 doi "https://doi.org/10.3389/fimmu.2022.983771" @default.
• W4306385659 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36325355" @default.
• W4306385659 hasPublicationYear "2022" @default.
• W4306385659 type Work @default.
• W4306385659 citedByCount "0" @default.
• W4306385659 crossrefType "journal-article" @default.
• W4306385659 hasAuthorship W4306385659A5004617126 @default.
• W4306385659 hasAuthorship W4306385659A5006506403 @default.
• W4306385659 hasAuthorship W4306385659A5009502823 @default.
• W4306385659 hasAuthorship W4306385659A5027482571 @default.
• W4306385659 hasAuthorship W4306385659A5031977714 @default.
• W4306385659 hasAuthorship W4306385659A5039690700 @default.
• W4306385659 hasAuthorship W4306385659A5045707345 @default.
• W4306385659 hasAuthorship W4306385659A5045965285 @default.
• W4306385659 hasAuthorship W4306385659A5050595115 @default.
• W4306385659 hasAuthorship W4306385659A5058103666 @default.
• W4306385659 hasAuthorship W4306385659A5074440260 @default.
• W4306385659 hasBestOaLocation W43063856591 @default.
• W4306385659 hasConcept C104317684 @default.
• W4306385659 hasConcept C126322002 @default.
• W4306385659 hasConcept C143998085 @default.
• W4306385659 hasConcept C145059251 @default.
• W4306385659 hasConcept C203014093 @default.
• W4306385659 hasConcept C2776694085 @default.
• W4306385659 hasConcept C2776755627 @default.
• W4306385659 hasConcept C2777938653 @default.
• W4306385659 hasConcept C2778461978 @default.
• W4306385659 hasConcept C2779263901 @default.
• W4306385659 hasConcept C2779338263 @default.

• next